Applicants respectfully request that the Examiner disregard the Preliminary Amendment of April 5, 2001. Applicants will effect changes through amendment where needed.

II. In the Claims (Clean Sheet)

4. A method of treating rheumatoid arthritis by modulating the reactivity of lymphocytes associated with said disease, comprising the step of administering a pharmaceutical composition comprising an effective amount of HC gp-39 or fragments thereof, and a pharmaceutically acceptable carrier, wherein said lymphocytes are reactive to antigens other than HC gp-39 which are present in the same tissue as HC gp-39.

5. The method of claim 4, wherein said fragments are selected from one or more of SEQ ID NO:1(FGRSFTLAS), SEQ ID NO:2(FTLASSETG), SEQ ID NO3(YDDQESVKS), SEQ ID NO:4(FSKIASNTQ), SEQ ID NO:5(PTFGRSFTLASSE), SEQ ID NO:6(PTFGRSFTLASSETGVG), SEQ ID NO:7(VGYDDQESVKSKV), and SEQ ID NO:8(SQRFSKIASNTQSR).

6. The method of claim 5, wherein said fragments are selected from one or more of SEQ ID NO:5(PTFGRSFTLASSE), SEQ ID NO:6(PTFGRSFTLASSETGVG), SEQ ID NO:7(VGYDDQESVKSKV), and SEQ ID NO:8(SQRFSKIASNTQSR).

10. A method for modulating the reactivity of lymphocytes that are reactive to antigens other than HC gp-39 which are present in the same tissue as HC gp-39, comprising the step of administering a pharmaceutical composition comprising an effective amount of HC gp-39 or fragments thereof, and a pharmaceutically acceptable carrier, whereby the reactivity of said lymphocytes is modulated.

11. The method of claim 4, wherein said fragments are selected from one or more of SEQ ID NO:1(FGRSFTLAS), SEQ ID NO:2(FTLASSETG), SEQ ID NO3(YDDQESVKS), SEQ ID NO:4(FSKIASNTQ), SEQ ID NO:5(PTFGRSFTLASSE),

SEQ ID NO:6(PTFGRSFTLASSETGVG), SEQ ID NO:7(VGYDDQESVKSKV), and SEQ ID NO:8(SQRFSKIASNTQSR).

12. The method of claim 5, wherein said fragments are selected from one or more of SEQ ID NO:5(PTFGRSFTLASSE), SEQ ID NO:6(PTFGRSFTLASSETGVG), SEQ ID NO:7(VGYDDQESVKSKV), and SEQ ID NO:8(SQRFSKIASNTQSR).

16. A method of treating an autoimmune disease by modulating the reactivity of lymphocytes associated with said disease, comprising the step of administering a pharmaceutical composition comprising an effective amount of HC gp-39 or fragments thereof, and a pharmaceutically acceptable carrier, wherein said lymphocytes are reactive to antigens other than HC gp-39 which are present in the same tissue as HC gp-39.